Apnimed's sleep apnea asset goes 2 for 2 in phase 3, solidifying star potential

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the number of nightly breath-stopping events by 46.8%, hitting the test's primary endpoint.